Sam Chun Dang Pharm. Co. Ltd (KQ:000250) — Market Cap & Net Worth
Market Cap & Net Worth: Sam Chun Dang Pharm. Co. Ltd (000250)
Sam Chun Dang Pharm. Co. Ltd (KQ:000250) has a market capitalization of $2.37 Billion (₩3.50 Trillion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #5605 globally and #125 in its home market, demonstrating a -0.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sam Chun Dang Pharm. Co. Ltd's stock price ₩163500.00 by its total outstanding shares 21405800 (21.41 Million). Also see 000250 current and non-current assets for a full breakdown of the balance sheet.
Sam Chun Dang Pharm. Co. Ltd Market Cap History: 2015 to 2026
Sam Chun Dang Pharm. Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $131.70 Million to $2.37 Billion (30.22% CAGR). Also see Sam Chun Dang Pharm. Co. Ltd (000250) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Sam Chun Dang Pharm. Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$234.31 Billion | 1.01% | #14 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$234.31 Billion | 1.01% | #14 of 1384 |
Weight: Sam Chun Dang Pharm. Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sam Chun Dang Pharm. Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sam Chun Dang Pharm. Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 000250 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Sam Chun Dang Pharm. Co. Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.64x
Sam Chun Dang Pharm. Co. Ltd's market cap is 0.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $168.57 Million | $147.37 Billion | $8.71 Billion | 0.00x | 0.02x |
| 2017 | $223.34 Million | $160.59 Billion | $12.51 Billion | 0.00x | 0.02x |
| 2018 | $550.05 Million | $159.96 Billion | $8.75 Billion | 0.00x | 0.06x |
| 2019 | $516.09 Million | $186.60 Billion | $10.45 Billion | 0.00x | 0.05x |
| 2020 | $1.19 Billion | $166.86 Billion | -$965.68 Million | 0.01x | N/A |
| 2021 | $628.85 Million | $167.27 Billion | -$16.56 Billion | 0.00x | N/A |
| 2022 | $635.38 Million | $177.34 Billion | $5.84 Billion | 0.00x | 0.11x |
| 2023 | $1.12 Billion | $192.67 Billion | -$10.38 Billion | 0.01x | N/A |
| 2024 | $2.15 Billion | $210.92 Billion | -$10.92 Billion | 0.01x | N/A |
| 2025 | $3.37 Billion | $231.81 Billion | $5.26 Billion | 0.01x | 0.64x |
Competitor Companies of 000250 by Market Capitalization
Companies near Sam Chun Dang Pharm. Co. Ltd in the global market cap rankings as of September 18, 2026. Review Sam Chun Dang Pharm. Co. Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sam Chun Dang Pharm. Co. Ltd by market ranking:
- ST Pharm Co.Ltd (KQ:237690): Ranked #8267 globally with a market cap of $1.16 Billion USD ( ₩1.71 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9464 globally with a market cap of $884.84 Million USD ( ₩1.31 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10523 globally with a market cap of $713.20 Million USD ( ₩1.05 Trillion KRW).
- Mezzion Pharma Co.Ltd (KQ:140410): Ranked #13136 globally with a market cap of $429.17 Million USD ( ₩633.28 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #8267 | ST Pharm Co.Ltd | KQ:237690 | $1.16 Billion | ₩91900.00 |
| #9464 | NatureCell Co.Ltd | KQ:007390 | $884.84 Million | ₩24600.00 |
| #10523 | Oscotec Inc | KQ:039200 | $713.20 Million | ₩37450.00 |
| #13136 | Mezzion Pharma Co.Ltd | KQ:140410 | $429.17 Million | ₩74100.00 |
Sam Chun Dang Pharm. Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Sam Chun Dang Pharm. Co. Ltd's market cap moved from $131.70 Million to $ 2.37 Billion, with a yearly change of 30.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩2.37 Billion | -29.68% |
| 2025 | ₩3.37 Billion | +56.57% |
| 2024 | ₩2.15 Billion | +92.11% |
| 2023 | ₩1.12 Billion | +76.48% |
| 2022 | ₩635.38 Million | +1.04% |
| 2021 | ₩628.85 Million | -47.20% |
| 2020 | ₩1.19 Billion | +130.77% |
| 2019 | ₩516.09 Million | -6.17% |
| 2018 | ₩550.05 Million | +146.28% |
| 2017 | ₩223.34 Million | +32.49% |
| 2016 | ₩168.57 Million | +28.00% |
| 2015 | ₩131.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Sam Chun Dang Pharm. Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.37 Billion USD |
| MoneyControl | $2.37 Billion USD |
| MarketWatch | $2.37 Billion USD |
| marketcap.company | $2.37 Billion USD |
| Reuters | $2.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more